Abstract. The present study aimed to explore the role of histone chaperone anti-silencing function 1B (ASF1B) in pancreatic cancer and the underlying mechanism. The biological function of ASF1B was investigated in pancreatic cancer cell lines (PANC-1 and SW1990) and a mouse xenograft model. Chromatin immunoprecipitation was used to detect the effect of ASF1B on the transcriptional activity of c-Myc. ASF1B was highly expressed in pancreatic adenocarcinoma (PAAD) samples from The Cancer Genome Atlas. ASF1B expression was positively associated with poor survival rates in patients with PAAD. Silencing of ASF1B in PANC-1 and SW1990 cells inhibited cell proliferation, migration and invasion, and induced apoptosis. Mechanistically, ASF1B increased H3K56 acetylation (H3K56ac) in a CREB-binding protein (CBP)-dependent manner. ASF1B promoted H3K56ac at the c-Myc promoter and increased c-Myc expression. In PANC-1 and SW1990 cells, the CBP inhibitor curcumin and the c-Myc inhibitor 10058-F4 reversed the promoting effects of ASF1B on cell proliferation, migration and invasion. In the mouse xenograft model, ASF1B silencing inhibited tumor growth, and was associated with low H3K56ac and c-Myc expression.

Introduction

Pancreatic cancer is one of the most common digestive system malignancies with a 5-year survival rate of 9% in 2008-2014 in the United States (1). At present, surgery is the most efficient therapy for pancreatic cancer; however, only ~20% of patients are diagnosed with surgically resectable disease (2). Furthermore, metastasis occurs in patients undergoing extensive resection (3,4). Metastatic response and progression of pancreatic cancer contribute to poor clinical outcomes (5). The pathogenesis of pancreatic cancer is complicated and involves various processes and signaling pathways (6,7). It is a priority to understand the mechanisms underlying the development and progression of pancreatic cancer.

Anti-silencing function 1 (ASF1) comprises two subtypes, ASF1A and ASF1B, which share a 70% sequence homology (8,9). ASF1B is a histone H3/H4 chaperone involved in DNA repair, replication and transcriptional regulation (10). ASF1B controls chromatin function and has been demonstrated to participate in tumorigenesis (11). Previous studies have determined that ASF1B is closely associated with the development and progression of numerous cancer types, such as prostate, breast and cervical cancer (12,13). In addition, ASF1B is frequently highly expressed in pancreatic cancer specimens and is closely associated with poor prognosis (14). Inhibition of ASF1B in pancreatic cancer cells enhances cisplatin sensitivity, inhibits micrometastasis and results in tumor cell death (14,15). In addition, c-Myc serves as an essential cancer-related transcription factor involved in diverse critical biological processes of cancer development (16-18). c-Myc has been reported to serve a critical role in modulating pancreatic cancer progression (19,20); however, the association between c-Myc and ASF1B in the modulation of pancreatic cancer progression remains unclear.

Epigenetic regulation serves as a program by which gene expression is modulated by events other than genomic alterations (21). Due to the extensive effect of epigenetic regulation on gene expression and genomic stability, it serves a fundamental role in a number of physiological and...
pathological processes, and influences carcinogenesis from initiation to progression (22), thus serving as a potential driver of tumorigenesis (21,23). As a common epigenetic regulator, histone acetylation serves a crucial role in the modulation of cancer development (24). Furthermore, it has been reported that ASF1 promotes anti-viral immune activity by associating with CREB-binding protein (CBP) to mediate H3K56 acetylation (H3K56ac) at the promoter of interferon β (25). Multi-site substrate recognition in ASF1-related histone H3K56ac through regulator of Tyl transposition 109 has also been identified (26). CBP is an essential transcriptional co-activator for a number of DNA-binding transcription factors and acts as a histone acetyltransferase (27). The CBP-mediated acetylation of H3K56 is involved in the modulation of cell proliferation and cancer (28). However, the association of ASF1B with CBP and H3K56ac in the development of pancreatic cancer remains elusive.

The present study aimed to explore the role and the underlying mechanism of ASF1B in the modulation of pancreatic cancer. The present study revealed that ASF1B promoted pancreatic cancer progression by activating c-Myc through CBP-mediated H3K56ac.

Materials and methods

Clinical pancreatic cancer samples. A total of 31 clinical pancreatic cancer samples were obtained from the Cancer Hospital Affiliated to Zhengzhou University (Zhengzhou, China) between May 2019 and December 2020. Clinicopathological information of patients is shown in Table I. The inclusion criteria were: Patients were diagnosed by clinical and pathological examination by two clinicians; no systemic or local therapy was administered before the surgery; and written informed consent was obtained from each patient before using the collected samples. The exclusion criteria were: Patients with cirrhosis and coagulation dysfunction; patients with serious cardiovascular and visceral diseases; patients with a history of second primary malignant tumors; and patients with mental illness or confused consciousness. The present study included 19 male and 12 female patients with an age range of 49-75 years (median age, 63.45±7.54 years). The pancreatic cancer tissues and corresponding para-neoplastic tissues obtained from the patients were immediately frozen in liquid nitrogen, followed by storage at -80˚C prior to further analysis. The present study was performed in accordance with the World Medical Association guidelines and approved by the Ethics Committee of Cancer Hospital Affiliated to Zhengzhou University (Ethics No. 2019-05-006; Zhengzhou, China).

Bioinformatics analysis. The data for ASF1B mRNA expression in pancreatic cancer and normal specimens were from Gene Expression Profiling Interactive Analysis (GEPIA) (29) (http://geopia.cancer-pku.cn/). The Cancer Genome Atlas (TCGA; ID, TCGA-PAAD; https://portal.gdc.cancer.gov/) data were used for GEPIA. According to ASF1B expression, the top and bottom 25% patients with pancreatic cancer were divided into high and low expression groups. The overall survival of 90 patients with pancreatic cancer was estimated using GEPIA with a cutoff value of 25%. Kaplan-Meier analysis was used for analyzing the difference of overall survival between the high and low expression groups using the log-rank test. Gene Set Enrichment Analysis (GSEA; version 4.2.1; h.all.v7.1 symbols.gmt; https://www.gsea-msigdb.org/gsea/index.jsp) was performed using R (version 3.4.1; https://cran.r-project.org/index.html) and the R clusterProfiler package (Bioconductor version 3.10; http://www.bioconductor.org/packages/3.10/bioc/html/clusterProfiler.html) (30) to explore signaling pathways.

Cell culture. PANC-1 (cat. no. CL-0184), CFPAC-1 (cat. no. CL-0059), PaCa-2 (cat. no. CL-0627) and HPAF-II (cat. no. CL-0611) pancreatic adenocarcinoma (PAAD) cell lines were purchased from Procell Life Science & Technology Co., Ltd., and the SW1990 (cat. no. CRL-2172) cell line was purchased from American Type Culture Collection. PANC-1 and SW1990 cells exhibiting epithelial morphology were used throughout the study. PANC-1 cells were cultured in DMEM (cat. no. 11965092; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (cat. no. SH30406.02; HyClone; Cytiva) and 1% penicillin-streptomycin solution (Beyotime Institute of Biotechnology). SW1990 cells were cultured in Leibovitz's L-15 medium (cat. no. 30-2008; American Type Culture Collection) supplemented with 10% FBS and 1% penicillin-streptomycin solution. CFPAC-1 cells were cultured in Iscove's Modified Dulbecco Medium (Procell Life Science & Technology Co., Ltd.) supplemented with 10% FBS and 1% penicillin-streptomycin solution. PaCa-2 cells were cultured in DMEM supplemented with 10% FBS, 2.5% horse serum (Procell Life Science & Technology Co., Ltd.) and 1% penicillin-streptomycin solution. HPAF-II cells were cultured in Minimum Essential Medium (Procell Life Science & Technology Co., Ltd.) supplemented with 10% FBS and 1% penicillin-streptomycin solution. All cell lines were maintained at 37˚C in a 5% CO2 air atmosphere and 100% air, respectively.

The CBP inhibitor curcumin and c-Myc inhibitor 10058-F4 were purchased from MedChemExpress. Curcumin and 10058-F4 were used to treat cells at a concentration of 100 µM for 24 h at 37˚C.

Plasmids, small interfering RNA (siRNA/ si) and transfection. To construct Flag-tagged ASF1B, total RNAs was extracted from PANC-1 cells using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.). The full coding region of the ASF1B gene was obtained by PCR with the specific primers of forward, 5'-CCC AAGCTTATGGCAGGTTGCGTGTCT-3' (HindIII) and reverse, 5'-CGGGAATCTCTAGACTGCTAGGAGGAACT-3' (BamHI) using PrimeSTAR HS DNA Polymerase (Takara Biotechnology Co., Ltd.). The thermocycling conditions were: 98˚C for 10 sec, followed by 30 cycles of 55˚C for 5 sec and 72˚C for 1 min. The PCR products were ligated into the p3XFLAG-CMV™-14 expression vector (MilliporeSigma) using the In-Fusion HD Cloning Kit (Takara Biotechnology Co., Ltd.). Empty vector was used as the negative control. siRNAs specific for ASF1B and CBP, and the non-targeting negative controls were obtained from TsingKe Biological Technology. The Homo sapiens siRNA sequences were as follows: si-ASF1B-1, 5'-GTTTACTCGAGTTGGGCTA CTA-3'; si-ASF1B-2, 5'-GGTGACCCGCTTCCATAT
PANC-1 and SW1990 cells (1x10^5 cells/well) were plated following transfection. The Cell Counting Kit-8 (CCK-8) assay was performed using CCK-8 (Dojindo Molecular Technologies, Inc.) according to the manufacturer's instructions. Apoptotic cells were analyzed using flow cytometry (Accuri-C6 plus; BD Biosciences). The number of apoptotic cells was analyzed using FlowJo software (v7.6.5; Tree Star, Inc.). The time interval between transfection and subsequent experimentation was <1 week.

Transwell assays. For cell migration assays, 1x10^5 transfected PANC-1 and SW1990 cells were plated in the upper chamber of a Corning® FluoroBlok™ 24-well Transwell system (Costar; Corning, Inc.). The cells in the upper chamber were maintained in DMEM or Leibovitz's L-15 base medium without serum. The lower chamber was filled with DMEM or Leibovitz's L-15 medium supplemented with 10% FBS. After 12 h of incubation at 37°C, the cells that had migrated into the lower chamber were fixed with 4% paraformaldehyde for 30 min at room temperature and stained with 0.5% crystal violet (Beyotime Institute of Biotechnology) for 30 min at room temperature. For cell invasion assays, the Transwell system was pre-coated with 100 µl Matrigel (Invitrogen; Thermo Fisher Scientific, Inc.) for 4 h at 37°C. The other steps were the same as for the migration assay. Images were captured under a light microscope (Eclipse 80i; Nikon Corporation). The migrated and invaded cells in five randomly selected fields of view in the lower chamber were counted to calculate cell migration and invasion. Both the migration and invasion assays were performed in triplicate.

Reverse transcription-quantitative PCR (RT-qPCR). Total RNAs was extracted from the human specimens and PANC-1 and SW1990 cell lines using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.). First-strand cDNA was synthesized using the PrimeScript™ RT Master Mix (cat. no. RR036A; Takara Biotechnology Co., Ltd.). The reverse transcription conditions were 37°C for 15 min followed by 85°C for 5 sec. qPCR was performed using the TB Green Fast qPCR Mix (cat. no. RR430A; Takara Biotechnology Co., Ltd.). Relative expression of the target genes was calculated according to the 2^ΔΔCq method by normalizing to the β-actin internal control (31). The Homo sapiens primer sequences were as follows: ASF1B forward, 5'-GATCAGCTTCGAGTGCGAGTG-3' and reverse, 5'-TGTTAGGGTGCAATGAGTGAAG-3'; c-Myc forward, 5'-GGCTCTGGCAAAAGGCTCA-3' and reverse, 5'-CTGGCTAGTGTTGGCTGTATGT-3'; and β-actin forward, 5'-GATTCCTATGTGGGACGA-3' and reverse, 5'-GCAAATGGATGCTTGAGAG-3'.

Table I. Clinicopathological information of patients with pancreatic cancer.

| Variables | Cases, n (%) |
|-----------|--------------|
| Sex       |              |
| Male      | 19 (61.29)   |
| Female    | 12 (38.71)   |
| Age, years|              |
| ≤60       | 10 (32.26)   |
| >60       | 21 (67.74)   |
| Histopathology |         |
| Ductal adenocarcinoma | 22 (70.97) |
| Other     | 9 (29.03)    |
| Location  |              |
| Head of pancreas | 23 (74.19) |
| Other     | 8 (25.81)    |
| Grade     |              |
| G1        | 2 (6.45)     |
| G2        | 11 (35.48)   |
| G3        | 18 (58.06)   |
| Stage     |              |
| I         | 4 (12.90)    |
| II        | 9 (29.03)    |
| III       | 17 (54.84)   |
| IV        | 1 (3.23)     |

Cytokeratin 5 and 19 (cat. no. RR036A; Takara Biotechnology Co., Ltd.). The relative expression of Cytokeratin 5 and 19 was calculated according to the 2^ΔΔCq method by normalizing to the β-actin internal control (31). The Homo sapiens primer sequences were as follows: Cytokeratin 5 forward, 5'-GGAAGGTGCTGATAGCTCAGCG-3' and reverse, 5'-GCTGAGTTGCTGCTGTCGTCG-3'; and Cytokeratin 19 forward, 5'-ACACCTAGCTGAGTGCTGATG-3'.

Colony formation. Following transfection with siRNAs, empty vector or flag-tagged ASF1B, PANC-1 and SW1990 cells (1,000 cells/well) were plated in 6-well plates and treated with 100 µM curcumin or 100 µM 10058-F4 for 24 h at 37°C. Non-treated cells were used as the control group. The culture medium was replaced every 3 days. Colonies were fixed with 4% paraformaldehyde for 30 min at room temperature and stained with 0.5% crystal violet (Beyotime Institute of Biotechnology) for 1 h at room temperature, and images were captured. Colonies with at least 50 cells were counted using ImageJ software (version 5.0; National Institutes of Health).
Western blot analysis. Total proteins were extracted from the collected tissue samples and cell lines using RIPA buffer (Cell Signaling Technology, Inc.). Protein concentrations were measured using the BCA Protein Quantification Kit (Abbkine Scientific Co., Ltd.). Equal amounts (30 µg/lane) were loaded onto an 8% SDS-PAGE gel and transferred to PVDF membranes (MilliporeSigma). The membranes were blocked in 5% skimmed milk for 1 h at 37°C. Membranes were incubated with primary antibodies against ASF1B (dilution, 1:1,000; cat. no. ab235358; Abcam), Bax (dilution, 1:1,000; cat. no. ab32503; Abcam), Bel-2 (dilution, 1:1,000; cat. no. ab182858; Abcam), c-Myc (dilution, 1:1,000; cat. no. ab10910; Abcam), β-actin (dilution, 1:1,000; cat. no. ab8226; Abcam), H3 (dilution, 1:1,000; cat. no. ab791; Abcam) and H3K56ac (dilution, 1:1,000; cat. no. PA5-121083; Thermo Fisher Scientific, Inc.) overnight at 4°C. Membranes were then incubated with goat anti-rabbit (cat. no. ab7090), anti-mouse (cat. no. ab97040) and anti-rat (cat. no. ab7097) IgG H&L (HRP) secondary antibodies (dilution, 1:1,000; Abcam) for 1 h at room temperature. The bands were developed using BeyoECL Plus (Beyotime Institute of Biotechnology) and semi-quantified using ImageJ software (version 5.0; National Institutes of Health). To determine the protein half-life curves, the cells were treated with 25 µg/ml cycloheximide (CHX; MilliporeSigma) for 0-4 h at 37°C.

Chromatin immunoprecipitation (ChIP). ChIP was performed using a SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling Technology, Inc.) according to the manufacturer's instructions. Following transfection with si-ASF1B-2 or siNC, cells were incubated with 1% formaldehyde for 15 min at room temperature, washed twice with PBS, centrifuged at 500 x g for 10 min at 4°C, and collected in SDS lysis buffer (Beyotime Institute of Biotechnology). Chromatin prepared from the cells in a 15-cm dish was used to determine total DNA input and was incubated overnight with 10 µg anti-H3K56ac (cat. no. PA5-121083; Thermo Fisher Scientific, Inc.) or anti-IgG (cat. no. ab171870; Abcam) at 4°C. In each immunoprecipitation, 10 µg of the protein-chromatin complex was used. Following incubation with 70 µl protein G agarose beads (Upstate Biotechnology, Inc.) for 2 h at 4°C, the immune complexes were precipitated at 3,400 x g for 1 min at 4°C and washed with 1 ml low salt washing solution. After three washes of low salt, 1 ml high salt solution was added to the beads and incubated at 4°C for 5 min. The protein G agarose beads were precipitated by centrifugation at 3,400 x g for 1 min at 4°C and then the supernatant was used in the next step. The PCR procedure was performed as aforementioned with the following primer sequences for amplifying the c-Myc promoter: Forward, 5'-GTTTCACTGTTCCTGTGTT-3' and reverse, 5'-TTCTTTGTCATCGCATAACCC-3'.

Pancreatic cancer xenograft. A total of 10 male BALB/c nude mice (8 weeks old; 22±2 g; Jinan Pengyue Laboratory Animal Breeding Co., Ltd.) were divided into two groups (n=5 per group): Short hairpin RNA (sh)NC and shASF1B. All animal experiments in the present study were approved by the Ethics Committee of Cancer Hospital Affiliated to Zhengzhou University (Ethics No. 2019-05-006; Zhengzhou, China) and performed in accordance with the standards of Animal Care and Use and the Animal Welfare Act. The tumor volume limit (≤2 cm in any dimension) was the humane endpoint criterion for mouse euthanasia. Mice were raised in specific pathogen-free conditions with ad libitum access to food and water. Mice were killed at sacrifice by cervical dislocation with prior anesthesia injection of 3% sodium pentobarbital (30 mg/kg). Death was verified to be respiratory cardiac arrest for at least 10 min and the observation of pupil dilation. Tumor tissues were washed with ice-cold PBS, weighed and subjected to immunohistochemical staining.

Histological examination. Human para-neoplastic and pancreatic cancer tissues were subjected to immunohistochemical staining. Tumor tissues were collected from the xenograft mouse model. Tissues were sliced (thickness, 0.1 mm) and then fixed with 4% paraformaldehyde for 2 h, permeabilized in 0.5% Triton X-100 at room temperature for 10 min and coated with paraffin. Tissue sections were heated at 62°C for 20 min, dehydrated in xylene for 20 min, rehydrated in decreasing concentrations of ethyl alcohol (100, 100, 90, 80 and 70%) and 2 min each followed by boiling in 0.01 M citric acid (pH 6.0)
Scientific, Inc.) at room temperature for 15 min, followed by incubation at 4°C overnight with primary antibodies against rabbit anti-ASF1B (dilution, 1:20; cat. no. ab235358; Abcam) and rabbit anti-Ki67 (dilution, 1:50; cat. no. ab16667; Abcam). A goat anti-rabbit IgG H&L (Alexa Fluor 488) secondary antibody (dilution, 1:100; cat. no. ab150077; Abcam) was used for incubation at 37°C for 1 h. The color was developed by adding 0.5 ml 3,3′-diaminobenzidine solution for 20 min at room temperature. Images were captured under a light microscope (Eclipse 80i; Nikon Corporation). Ki67-positive cells were counted using ImageJ software (version 5.0; National Institutes of Health).

Apoptotic cells in the tumor tissues were detected using a TUNEL assay kit (Beyotime Institute of Biotechnology). The sections were fixed with 4% paraformaldehyde at 4°C for 1 h and washed twice with PBS for 20 min at room temperature. The sections were then incubated with 0.5% Triton X-100 and 3% H2O2 at room temperature for 10 min followed by incubation with 50 µl TUNEL reaction mixture (5 µl TdT enzyme and 45 µl fluorescent labeling solution) for 1 h at 37°C in the dark. After three washes with PBS, 1 µg/ml DAPI (Beyotime Institute of Biotechnology) was used for nuclear staining at room temperature for 10 min. The slides were mounted with antifade mounting medium (Wuhan Servicebio Technology Co., Ltd.). Images were captured using a fluorescence microscope (DMI6000B; Leica Microsystems GmbH). Images were captured using a fluorescence microscope (DMI6000B; Leica Microsystems GmbH). Five fields were selected for counting TUNEL-positive cells using ImageJ software (version 5.0; National Institutes of Health). A HE staining kit (Beyotime Institute of Biotechnology) was used to detect the histology of the harvested tumor tissues. Tissues were fixed with 4% paraformaldehyde for 24 h at room temperature, coated with paraffin and sectioned into 4-µm section. The sections were stained with hematoxylin for 10 min at room temperature followed by incubation with eosin for 30 sec at room temperature. Images were captured under a light microscope (Eclipse 80i; Nikon Corporation).

Statistical analysis. Data are presented as the mean ± SD. In vitro data were obtained from three independent experiments. Statistical analyses were performed using GraphPad Prism 7 software (GraphPad Software, Inc.). The paired and unpaired t-test was used for two-group comparisons. One-way ANOVA followed by Tukey’s post hoc test and two-way ANOVA followed by Bonferroni’s post hoc test were used for multiple-group comparisons. Brown-Forsythe and Bartlett’s tests were used to assess the normality and variance homogeneity. The correlation between ASF1B and c-Myc expression was analyzed using the linear regression test. P<0.05 was considered to indicate a statistically significant difference.

Results

ASF1B is highly expressed in pancreatic cancer and is closely associated with poor prognosis. To evaluate the potential association between ASF1B and pancreatic cancer, ASF1B expression was analyzed in PAAD samples from TCGA. ASF1B expression was significantly increased in primary tumor samples compared with normal samples (Fig. 1A). Kaplan-Meier analysis based on the PAAD samples from TCGA revealed that a high level of ASF1B was associated with poor overall survival of patients with pancreatic cancer (Fig. 1B). In the present study, 31 patients with pancreatic cancer were enrolled, and their tumor tissues were collected during surgery. RT-qPCR indicated that ASF1B mRNA expression was significantly higher in pancreatic cancer tissues than in adjacent normal controls (Fig. 1C). Immunohistochemical staining revealed that ASF1B was highly expressed in pancreatic cancer tissues compared with the adjacent normal controls (Fig. 1D). Consistently, ASF1B protein expression was higher in 12 randomly selected pancreatic cancer tissues than in paired adjacent normal controls (Fig. 1E). ASF1B expression was higher in PANC-1 and SW1990 cells than the other three cell lines (Fig. 1F), and thus, these two cell lines were used in subsequent experiments.

Silencing of ASF1B inhibits pancreatic cancer cell proliferation, migration and invasion, and induces apoptosis. Considering that ASF1B is highly expressed in pancreatic cancer, the present study aimed to investigate the effects of ASF1B silencing on pancreatic cancer cells. To this end, two different siRNA sequences specific to ASF1B were transfected into PANC-1 and SW1990 cells. ASF1B protein expression was significantly decreased by ASF1B siRNAs compared with siNC (Fig. 2A). Transfection of PANC-1 and SW1990 cells with ASF1B siRNAs significantly inhibited proliferation (Fig. 2B) and colony formation (Fig. 2C) compared with those of the cells transfected with siNC. Transfection of cells with ASF1B siRNAs significantly increased the apoptosis of PANC-1 and SW1990 cells compared with transfection with siNC (Fig. 2D). In addition, Bax was upregulated and Bcl-2 was downregulated following transfection with ASF1B siRNAs compared with the siNC group (Fig. 2E).

The migration and invasion of PANC-1 and SW1990 cells following transfection with ASF1B siRNAs or siNC were detected using a transwell assay. As shown in Fig. 2F and G, the migration and invasion of PANC-1 and SW1990 cells were significantly inhibited following transfection with ASF1B siRNAs compared with the siNC group. Consistently, ASF1B siRNA transfection significantly inhibited wound healing at 12 h of incubation compared with the siNC group (Fig. 2H and I).

ASF1B induces c-Myc expression in pancreatic cancer cells. Furthermore, the underlying mechanism by which ASF1B exerts its effects on pancreatic cancer cells was explored. GSEA predicted a positive association between ASF1B and the c-Myc signaling pathway (Fig. 3A). The association between ASF1B and the c-Myc signaling pathway was confirmed in subsequent experiments. The mRNA and protein expression levels of c-Myc were downregulated in cells transfected with ASF1B siRNAs compared with siNC (Fig. 3B and C). However, c-Myc protein levels were upregulated in cells transfected with Flag-tagged ASF1B overexpression plasmid compared with the negative control (Fig. 3D).
c-Myc was detected after treatment with the protein synthesis inhibitor, CHX. As shown in Fig. 3E, ASF1B siRNA regulated c-Myc stability in PANC-1 and SW1990 cells. The protein levels and half-life of c-Myc protein were decreased significantly in the ASF1B siRNA group compared with the siNC group (Fig. 3F and G). Furthermore, a linear regression test
revealed a positive correlation between ASF1B and c-Myc mRNA expression in 31 pancreatic cancer tissues ($R^2=0.1881$; $P=0.0148$; Fig. 3H).

**Figure 2.** Silencing of ASF1B inhibits pancreatic cancer cell proliferation, migration and invasion, and induces apoptosis. (A) PANC-1 and SW1990 cells were transfected with ASF1B siRNAs (si-ASF1B-1 and si-ASF1B-2) or siNC. Protein levels of ASF1B were measured by western blotting. (B) Cell proliferation, (C) colony formation, (D) apoptosis, and (E) expression levels of Bax and Bcl-2 were detected by Cell Counting Kit-8 assays, colony formation assays, flow cytometry and western blotting, respectively. (F) PANC-1 and (G) SW1990 cells were transfected with ASF1B siRNAs (si-1 and si-2) or siNC. Cell migration and invasion were detected by transwell assays. Magnification, x100; scale bar, 100 $\mu$m. The wound distance of (H) PANC-1 and (I) SW1990 cell cultures was detected using a scratch test. Magnification, x40; scale bar, 200 $\mu$m. Data are presented as the mean ± SD (n=3). *$P<0.05$, **$P<0.01$, ***$P<0.001$ vs. siNC group. Data in (B) were analyzed using two-way ANOVA followed by Bonferroni's post hoc test. Other data were analyzed using one-way ANOVA followed by Tukey's post hoc test. Brown-Forsythe and Bartlett's tests were used to assess the normality and variance homogeneity. ASF1B, anti-silencing function 1B; NC, negative control; OD, optical density; siRNA/si, small interfering RNA.

ASF1B induces c-Myc expression through CBP-mediated H3K56ac. The present study next investigated whether ASF1B upregulates c-Myc expression by inducing H3K56ac.
In PANC-1 and SW1990 cells, silencing of ASF1B by specific siRNAs significantly inhibited the protein levels of acetylated H3K56 (Fig. 4B), indicating that ASF1B is a key regulator of H3K56ac. Silencing of acetyltransferase CBP with specific siRNAs inhibited the expression of acetylated H3K56 and c-Myc induced by ASF1B (Fig. 4C). The proof of successful
transfection of si-CBP is shown in Fig. S1. Consistently, the CBP inhibitor, curcumin, inhibited the expression of acetylated H3K56 and c-Myc induced by ASF1B (Fig. 4D). The effects of ASF1B on the transcriptional activity of c-Myc were analyzed by ChIP. In siNC transfected PANC-1 and SW1990 cells, 33.9 and 81.4-fold enrichment of the promoter amplification of c-Myc was observed in AS1B+si-CBP transfection compared to siNC. The schematic representation of the proposed mechanism of ASF1B in epigenetic regulation of c-Myc mRNA expression is shown in Fig. 4E. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. Data were analyzed using one-way ANOVA followed by Tukey's post hoc test. Brown-Forsythe and Bartlett's tests were used to assess the normality and variance homogeneity. ASF1B, anti-silencing function 1B; CBP, CREB binding protein; Con, control (empty vector); H3K56ac, histone H3 lysine 56 acetylation; NC, negative control; ns, not significant; siRNA/si, small interfering RNA.
c-Myc was observed using anti-H3K56ac antibodies compared with anti-IgG (Fig. 4E). However, no significant enrichment of the c-Myc promoter was observed in ASF1B-silenced PANC-1 (P=0.847) and SW1990 (P=0.522) cells. These data revealed that ASF1B promoted CBP-mediated H3K56ac to enhance the transcriptional activity of c-Myc in pancreatic cancer cells (Fig. 4F).

ASF1B contributes to the progression of pancreatic cancer by modulating CBP/H3K56ac/c-Myc signaling in vitro. CCK-8 assays revealed that the overexpression of ASF1B enhanced the proliferation of PANC-1 and SW1990 cells, and the CBP inhibitor curcumin and the c-Myc inhibitor 10058-F4 blocked this enhancement (Fig. 5A). In addition, treatment with curcumin and 10058-F4 significantly inhibited the colony formation of PANC-1 and SW1990 cells induced by ASF1B overexpression (Fig. 5B). Transwell assay results demonstrated that migration and invasion induced by ASF1B overexpression in PANC-1 and SW1990 cells were significantly inhibited.
In summary, these data indicated that ASF1B promoted the progression of pancreatic cancer by activating CBP/H3K56ac/c-Myc signaling in vitro.

**Silencing of ASF1B reduces c-Myc expression and pancreatic cancer growth in vivo.** The present study further determined the role of ASF1B in pancreatic cancer development in vivo. Therefore, pancreatic cancer xenografts were established by injecting BALB/c nude mice with PANC-1 cells that were pre-transfected with shNC or shASF1B. The proof of successful transfection of shASF1B is shown in Fig. S2. Compared with those in the shNC group, the mice in the shASF1B group had a lower tumor weight and volume at day 20, 25 and 30 (Fig. 6A-C). HE staining results showed that, compared with the shNC group, the shASF1B group tumor tissues exhibited focal necrosis (Fig. 6D). The percentage of Ki67-positive cells was reduced, and the TUNEL-positive cell rate was increased significantly in the tumor tissues of the shASF1B group (Fig. 6D-F). Furthermore, ASF1B was weakly expressed in the shASF1B group, with low expression of H3K56ac and c-Myc (Fig. 6G and H), indicating that silencing of ASF1B inhibited c-Myc expression and tumor growth in vivo.

**Discussion**

Pancreatic cancer is one of the deadliest malignancies of the digestive system worldwide (32). It has been previously reported that the histone chaperone ASF1B is a biomarker for predicting the outcome of human cancers, including pancreatic cancer (15,33). Silencing of ASF1B influences prostate cancer cell apoptosis by inhibiting PI3K/AKT signaling (11). ASF1B increases migration and growth of clear cell renal cell carcinoma by activating AKT signaling (34). Silencing of ASF1B induces pancreatic cancer cell death and inhibits cancer cell micrometastasis via inactivation of the PI3K/AKT signaling pathway (14,15). By analyzing TCGA, ASF1B was identified to be highly expressed in PAAD samples, and its expression was positively associated with poor survival rate. In the present study, high ASF1B expression was also demonstrated in 31 patients with pancreatic cancer. In PANC-1 and SW1990 cells, ASF1B silencing repressed cell proliferation, migration and invasion, indicating the oncogenic role of ASF1B in pancreatic cancer. In addition, to the best of our knowledge, the present study was the first to demonstrate that ASF1B induced c-Myc expression through CBP-mediated H3K56ac. ASF1B exerted oncogenic effects in pancreatic cancer, possibly through the activation of CBP/H3K56ac/c-Myc signaling.
c-Myc has been recognized as a critical regulator of pancreatic cancer progression (19). Various factors that target c-Myc expression have been demonstrated to be effective in regulating tumor progression. For instance, pescadillo ribosomal biogenesis factor 1 enhances resistance to extra-terminal inhibitors and cell proliferation by increasing c-Myc expression in pancreatic cancer (35). F-box and WD repeat domain containing 7 is a negative modulator of glycolytic metabolism that regulates c-Myc/thioredoxin interacting protein signaling in pancreatic cancer (36). Bromodomain PHD finger transcription factor is critical for transcriptional activation of c-Myc in tumorigenesis (37). Proteasome activator subunit 3 increases pancreatic cancer progression via c-Myc/glycolysis signaling (38). The cooperation of dysregulated KRAS and Myc via inhibition of the type I interferon pathway achieves immune evasion in pancreatic cancer cells (39). The present study revealed that ASF1B was positively associated with c-Myc and that ASF1B promoted c-Myc expression in pancreatic cancer cells. To the best of our knowledge, the present study was the first to demonstrate an association between ASF1B and c-Myc in the development of pancreatic cancer, and presented a novel mechanism of ASF1B-mediated pancreatic cancer involving c-Myc activation.

Epigenetic regulation serves a critical role in cancer development, and histone acetylation modulates cancer-related gene expression (40,41). Histone H3K56ac and histone acetyltransferase CBP are involved in cancer progression. It has been reported that hypoxia-provoked K63-polyubiquitinated herpes virus-associated ubiquitin-specific protease affects CBP-regulated acetylation of H3K56 on the promoters of hypoxia-inducible factor 1α-targeted genes to increase metastasis in tumor progression (42). mTORC2 signaling positively supports H3K56ac to regulate metabolic reprogramming in gliomas (43). Chromatin marks on Notch-related enhancers exhibit large-scale variations in H3K56ac upon activation (44). In addition, ASF1B is reportedly essential for regulating H3K56ac and this modification in gene transcription and replication (45,46). Genetic deletion of the H3K56 deacetylase enzyme sirtuin 6 leads to increased c-Myc transcription (47,48). The present study revealed that ASF1B enhanced c-Myc expression by modulating H3K56ac and promoting H3K56ac at the c-Myc promoter. These data revealed a novel mechanism involving ASF1B/CBP/H3K56ac/c-Myc in pancreatic cancer progression.

In conclusion, ASF1B promoted pancreatic cancer progression by activating c-Myc through CBP-mediated H3K56ac. The present findings provide novel insights into the mechanism by which ASF1B modulates pancreatic cancer development via CBP/H3K56ac/c-Myc signaling. Therefore, ASF1B may serve as a potential target for pancreatic cancer therapy.

Acknowledgements
Not applicable.

Funding
The present study was supported by National Natural Science Foundation of China joint fund project (grant no. 1404820), Tackling Key Problems of Science and Technology in Henan Province (grant no. 21202301037) and Henan Medical Science and Technology Research plan project (joint construction) (grant no. lhgj20190628).

Availability of data and material
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MZha conceived and designed the study. LZ, MZho, EW, and BM performed experiments. QinL, XW, YW, and QioL analyzed and interpreted the data. MZha wrote the manuscript. All authors read and approved the final manuscript. MZha, YW and QioL confirm the authenticity of all the raw data.

Ethics approval and consent to participate
Animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals. Animal and patient experiments were approved by the Ethics Committee of Cancer Hospital Affiliated to Zhengzhou University (Ethics No. 2019-05-006; Zhengzhou, China). This research was conducted under the guidance of the Declaration of Helsinki. All patients provided written informed consent.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69: 7-34, 2019.
2. Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet 388: 73-85, 2016.
3. Kang MJ, Jang JY and Kim SW: Surgical resection of pancreatic head cancer: What is the optimal extent of surgery? Cancer Lett 382: 259-265, 2016.
4. Garrido-Laguna I and Hidalgo M: Pancreatic cancer: From state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 12: 319-334, 2015.
5. Giovannetti E, van der Borden CL, Frampton AE, Ali A, Firuzi O and Peters GJ: Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Semin Cancer Biol 44: 43-59, 2017.
6. Collisson EA, Bailey P, Chang DK and Biankin AV: Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 16: 207-220, 2019.
7. Ilic M and Ilic I: Epidemiology of pancreatic cancer. World J Gastroenterol 22: 9694-9705, 2016.
8. Mousson F, Ochesnein F and Mann C: The histone chaperone Asf1 at the crossroads of chromatin and DNA checkpoint pathways. Chromosoma 116: 79-93, 2007.
9. Cote JM, Kuo YM, Henry RA, Scherman H, Krzizike DD and Andrews AJ: Two factor authentication: Asf1 mediates crosstalk between H3 K14 and K56 acetylation. Nucleic Acids Res 47: 7380-7391, 2019.
10. Paul PK, Rabaglia ME, Wang CY, Stapleton DS, Leng N, Kendzierski C, Lewis PW, Keller MP and Attie AD: Histone chaperone ASF1B promotes human β-cell proliferation via recruitment of histone H3.3. Cell Cycle 15: 3191-3202, 2016.
11. Han G, Zhang X, Liu P, Yu Q, Li Z, Yu Q and Wei X: Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer. Int J Oncol 53: 2056-2066, 2018.

12. Corpet A, De Koning L, Tödelling J, Savigoni A, Berger F, Lemaitre C, O’Sullivan RJ, Karlseder J, Barillot E, Asselain B, et al.: Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. EMBO J 30: 480-493, 2011.

13. Rosty C, Sheffer M, Tsafir D, Stransky N, Tsafir I, Peter M, de Crémont P, de La Ra, Salomon R, Dorval T, et al.: Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 24: 7094-7104, 2005.

14. Kim JH, Youn Y, Lee JC, Kim J, Ryu JK and Hwang JH: Downregulation of ASFB1 inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. Cancer Biomark 34: 647-659, 2022.

15. Wang K, Hao Z, Fu X, Li W, Jiao A and Hua X: Involvement of elevated ASFB1 in the poor prognosis and tumorigenesis in pancreatic cancer. Mol Cell Biochem 477: 1947-1957, 2022.

16. Thomas LR, Foshage AM, Weissmiller AM and Tansey WP: The MYC-WDR5 nexus and cancer. Cancer Res 75: 4012-4015, 2015.

17. Pelengaris S and Khan M: The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth. Expert Opin Ther Targets 7: 623-642, 2003.

18. Dang CV: MYC on the path to cancer. Cell 149: 22-35, 2012.

19. Wirth M, Mahboobi S, Kramer OH and Schneider G: Concepts to target MYC in pancreatic cancer. Mol Cancer Ther 15: 1792-1798, 2016.

20. Hogg SJ, Beavis PA, Dawson MA and Johnstone RW: Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov 19: 776-800, 2020.

21. Chen Y, Hong T, Wang S, Mo J, Tian T and Zhou X: Epigenetic modification of nucleic acids: From basic studies to medical applications. Chem Soc Rev 46: 2844-2872, 2017.

22. Dawson MA and Kouzarides T: Cancer epigenetics: From mechanism to therapy. Cell 150: 12-27, 2012.

23. Audia JE and Campbell RM: Histone modifications and cancer. Cold Spring Harb Perspect Biol 8: a019521, 2016.

24. Liu Z, Yang L, Sun Y, Xie X and Huang J: ASFIa enhances antiviral immune response by associating with CBP to mediate acetylation of H3K56 at the Ifnb promoter. Mol Immunol 78: 57-64, 2016.

25. Liu Z, Serra-Cardona A, Zhou H, Wang M, Yang N, Zhang Z and Xu RM: Multisite substrate recognition in asf1-dependent acetylation of active genes in drosophila. Front Cell Dev Biol 9: 740866, 2021.

26. Das C, Lucia MS, Hansen KC and Tyler JK: CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459: 113-117, 2009.

27. Tang Z, Kang B, Li C, Chen T and Zhang Z: GEPLA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 47: W556-W560, 2019.

28. Skalska L, Stojnic R, Li J, Fischer B, Cerda-Moya G, Sakai H, Tajbakhsh S, Russell S, Adryan B and Bray SJ: Chromatin signatures at Notch-regulated enhancers reveal large-scale changes in H3K56ac upon activation. EMBO J 34: 1889-1904, 2015.

29. Weng M, Yang Y, Feng H, Pan Z, Shen WH, Zou Y and Dong A: Histone chaperone ASFIa is involved in gene transcription activation in response to heat stress in Arabidopsis thaliana. Plant Cell Environ 37: 2128-2138, 2014.

30. Han J, Zhou H, Li Z, Xu RM and Zhang Z: Acetylation of lysine 56 of histone H3 catalyzed by RTT109 and regulated by ASFIa is required for replisome integrity. J Biol Chem 282: 28587-28596, 2007.

31. Sebastián C, Zwaans BM, Silberman DM, Gyemek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, et al.: The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151: 1185-1199, 2012.

32. Cai J, Zuo Y, Wang T, Cao Y, Cai R, Chen FL, Cheng J and Mu J: A crucial role of SUMOylation in modulating Sirt6 deacetylation of H3 at lysine 56 and its tumor suppressive activity. Oncogene 35: 4949-4956, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

INTERNATIONAL JOURNAL OF ONCOLOGY 62: 8, 2023